Black Swan Sale

50% Off Elite

Register Now!

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Last Close
Nov 26  •  04:00PM ET
154.37
Dollar change
-2.83
Percentage change
-1.80
%
IndexS&P 500 P/E33.77 EPS (ttm)4.57 Insider Own0.49% Shs Outstand283.05M Perf Week6.90%
Market Cap43.76B Forward P/E23.59 EPS next Y6.54 Insider Trans-1.34% Shs Float282.12M Perf Month5.84%
Enterprise Value45.33B PEG3.69 EPS next Q1.38 Inst Own91.13% Short Float1.34% Perf Quarter23.54%
Income1.30B P/S6.30 EPS this Y6.38% Inst Trans-0.22% Short Ratio2.06 Perf Half Y36.27%
Sales6.95B P/B6.48 EPS next Y10.05% ROA10.57% Short Interest3.78M Perf YTD14.91%
Book/sh23.82 P/C24.46 EPS next 5Y9.14% ROE20.62% 52W High160.27 -3.68% Perf Year15.34%
Cash/sh6.31 P/FCF37.99 EPS past 3/5Y3.02% 14.67% ROIC13.31% 52W Low96.43 60.09% Perf 3Y6.36%
Dividend Est.1.07 (0.69%) EV/EBITDA24.40 Sales past 3/5Y0.48% 5.41% Gross Margin56.15% Volatility4.09% 2.93% Perf 5Y42.04%
Dividend TTM0.99 (0.64%) EV/Sales6.52 EPS Y/Y TTM3.34% Oper. Margin22.60% ATR (14)4.40 Perf 10Y292.40%
Dividend Ex-DateJan 06, 2026 Quick Ratio1.52 Sales Y/Y TTM6.73% Profit Margin18.75% RSI (14)64.64 Recom2.05
Dividend Gr. 3/5Y5.63% 6.58% Current Ratio1.96 EPS Q/Q25.10% SMA204.42% Beta1.26 Target Price167.29
Payout21.71% Debt/Eq0.50 Sales Q/Q9.41% SMA509.23% Rel Volume1.80 Prev Close157.20
Employees17900 LT Debt/Eq0.45 EarningsNov 24 AMC SMA20024.97% Avg Volume1.83M Price154.37
IPONov 18, 1999 Option/ShortYes / Yes EPS/Sales Surpr.0.36% 0.36% Trades Volume3,294,173 Change-1.80%
Date Action Analyst Rating Change Price Target Change
Oct-08-25Upgrade UBS Neutral → Buy $170
Oct-08-25Initiated Rothschild & Co Redburn Buy $165
Feb-10-25Upgrade Barclays Underweight → Equal Weight $135 → $145
Aug-28-24Initiated Wells Fargo Overweight $157
Jul-10-24Upgrade Citigroup Neutral → Buy $135 → $150
Jun-27-24Downgrade Wolfe Research Outperform → Peer Perform
Jun-03-24Resumed Jefferies Hold $135
Apr-05-24Upgrade Stifel Hold → Buy $145 → $163
Dec-13-23Initiated Wolfe Research Outperform $140
Dec-12-23Downgrade BofA Securities Buy → Neutral $130 → $133
Nov-26-25 02:18PM
05:14AM
Nov-25-25 12:42PM
12:00AM
Nov-24-25 06:30PM
06:01PM Loading…
06:01PM
06:00PM
05:22PM
05:20PM
04:31PM
04:10PM
03:20AM
Nov-23-25 07:37AM
Nov-22-25 10:01PM
Nov-21-25 02:44PM
12:35PM Loading…
12:35PM
Nov-19-25 04:15PM
09:15AM
Nov-18-25 05:10PM
07:55AM
Nov-16-25 11:55PM
Nov-14-25 06:05PM
Nov-13-25 05:50PM
Nov-12-25 05:15PM
Nov-07-25 08:20AM
Nov-06-25 05:35PM
Nov-05-25 07:45AM
Oct-31-25 11:00AM
05:53AM
Oct-30-25 04:15PM
12:11PM Loading…
Oct-29-25 12:11PM
Oct-28-25 06:43AM
Oct-27-25 07:17PM
04:15PM
Oct-01-25 01:56PM
Sep-30-25 08:00AM
Sep-29-25 04:17PM
Sep-26-25 11:30AM
Sep-22-25 10:18AM
Sep-19-25 11:40AM
Sep-17-25 04:05PM
Sep-11-25 04:15PM
02:19PM
Sep-09-25 08:00AM
12:02AM
Sep-04-25 11:31PM
Sep-03-25 11:40AM
08:00AM
01:31AM
Sep-02-25 08:00AM
Sep-01-25 09:15AM
Aug-28-25 02:43PM
01:59PM
09:56AM
03:06AM
Aug-27-25 06:36PM
05:30PM
05:20PM
04:40PM
04:30PM
04:05PM
04:03PM
Aug-26-25 06:42PM
Aug-25-25 11:02PM
Aug-22-25 02:25PM
09:15AM
Aug-21-25 04:15PM
07:16AM
Aug-20-25 08:00AM
Aug-19-25 06:40PM
04:54PM
Aug-18-25 11:40AM
Aug-14-25 10:07AM
09:15AM
07:20AM
Aug-13-25 11:18AM
08:25AM
08:00AM
Aug-07-25 05:40PM
Aug-04-25 08:00AM
06:27AM
Jul-30-25 05:48AM
Jul-29-25 09:10AM
Jul-28-25 09:00PM
11:30AM
Jul-24-25 03:30PM
08:27AM
Jul-21-25 04:08AM
Jul-17-25 04:30PM
12:59PM
10:42AM
Jul-15-25 08:30AM
Jul-14-25 03:20PM
08:30AM
Jul-08-25 06:24AM
Jul-07-25 09:54AM
12:03AM
Jun-30-25 12:43PM
Jun-27-25 11:30AM
Jun-24-25 01:40AM
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gonsalves RodneyOfficerNov 26 '25Proposed Sale154.993,000464,956Nov 26 02:26 PM
MCDONNELL PADRAIGPresident and CEONov 18 '25Sale143.24911130,49232,058Nov 20 05:22 PM
MCDONNELL PADRAIGOfficerNov 18 '25Proposed Sale143.24911130,492Nov 18 10:37 AM
MCDONNELL PADRAIGPresident and CEONov 12 '25Option Exercise109.8612,4901,372,15145,938Nov 14 04:02 PM
MCDONNELL PADRAIGPresident and CEONov 12 '25Sale150.0012,4901,873,50033,448Nov 14 04:02 PM
MCDONNELL PADRAIGOfficerNov 12 '25Proposed Sale150.0012,4901,873,500Nov 12 10:03 AM
McMahon Robert W.Former OfficerSep 09 '25Proposed Sale126.215,781729,591Sep 09 04:26 PM
McMahon Robert W.Former OfficerSep 04 '25Proposed Sale128.6215,3031,968,224Sep 04 04:39 PM
MCDONNELL PADRAIGPresident and CEOSep 02 '25Sale124.882,000249,76033,448Sep 04 03:36 PM
MCDONNELL PADRAIGOfficerSep 02 '25Proposed Sale124.882,000249,760Sep 02 03:30 PM
McMahon Robert W.Former OfficerAug 29 '25Proposed Sale124.9628,0813,508,993Aug 29 03:46 PM
Ancher-Jensen HenrikFormer OfficerAug 29 '25Proposed Sale125.0421,6442,706,366Aug 29 09:59 AM
MCDONNELL PADRAIGPresident and CEOAug 01 '25Sale113.452,000226,90035,448Aug 04 04:15 PM
MCDONNELL PADRAIGOfficerAug 01 '25Proposed Sale113.452,000226,900Aug 01 10:32 AM
MCDONNELL PADRAIGPresident and CEOJul 01 '25Sale117.441,508177,10037,448Jul 03 04:46 PM
MCDONNELL PADRAIGOfficerJul 01 '25Proposed Sale117.441,508177,100Jul 01 12:45 PM
Brown Judy LDirectorJun 18 '25Sale116.5389041,677Jun 23 12:12 PM
Podolsky Daniel KDirectorMar 31 '25Sale116.461,819211,84435,737Apr 02 05:07 PM
Podolsky Daniel KDirectorMar 31 '25Proposed Sale116.461,819211,845Mar 31 01:21 PM
Gonsalves RodneyV.P., Corporate ControllerMar 17 '25Sale121.981,908232,69121,786Mar 18 02:17 PM
Gonsalves RodneyOfficerMar 17 '25Proposed Sale121.961,908232,692Mar 17 03:14 PM
Rataj Sue H.DirectorMar 06 '25Sale126.386,971881,00919,640Mar 07 04:11 PM
Rataj Sue H.DirectorMar 06 '25Proposed Sale126.386,971881,005Mar 06 02:27 PM
MCDONNELL PADRAIGPresident and CEOJan 21 '25Sale150.001,911286,65039,652Jan 23 07:20 PM
MCDONNELL PADRAIGOfficerJan 21 '25Proposed Sale150.001,911286,650Jan 21 10:53 AM